San Diego, 28 - 30 November 2018

Schedule

Create your personal agenda –check the favourite icon

Nov 2808:10
Conference pass

Keynote Opening Address: The impact of vaccine legislation on public health in California

Keynotes
Nov 2808:35
Conference pass

Addressing the epidemic of misinformation

Keynotes
  • What are the key drivers of hesitancy to vaccinate?
    • Complacency, convenience and confidence
  • What works in tackling misinformation and building trust?
    • E.g. what steps are being taken to counteract sophisticated social media campaigns of parent groups?
  • What responsibility do public health and education authorities have and how can companies get involved?
Nov 2809:20
Conference pass

Novel approaches to fighting infectious diseases and the increasing global threat of Anti-Microbial Resistance

Keynotes
  • What are the limitations in the approaches used to fight infections currently?
  • What new approaches should we be practicing that benefits us in the long-term?
Nov 2809:45
Conference pass

The evolution of antibody therapy for cancer

Keynotes
  • Progress in the development of antibody drug conjugates,bispecific antibodies, and fusion protein/antibodies
  • Novel approaches in antibody therapy- who is leading the next generation of antibody development?
  • What have been the most successful and least successful antibody therapies? Why?
  • How do we decide what level of toxicity is acceptable? Does this vary across indications?
Nov 2811:35
Conference pass

Advantages of using oral tablet vaccines for protection against influenza

Vaccine Development
Nov 2811:35
Conference pass

Synthetic DNA vaccines for cancer immunotherapy – Enabling CPI combinations and personalized treatments

Immuno-Oncology
Nov 2811:35
Conference pass

Designing innovative cohort adaptive sequential trials in oncology and other therapeutic areas

Clinical Trials
  • How can innovative trial design help speed the development process and make it more accurate?
  • Using one trial to address and identify the benefitting patient subpopulation
Nov 2812:05
Conference pass

Efficacy, Safety and immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Adults

Vaccine Development
  • Placebo-controlled Phase 3 efficacy results of QIV seasonal VLPs in healthy adults
  • Review of safety profile
  • Comparison of humoral and cell-mediated immune responses induced by VLPs in stratified age groups (18-49 and 50-64 years of age)
Nov 2812:05
Conference pass

An off-the-shelf dendritic cell vaccine candidate for treatment of CMV+ tumors

Immuno-Oncology
Nov 2812:05
Conference pass

Lung- MAP: using state-of-the-art genomic profiling to match patients to the most appropriate clinical trial

Clinical Trials
  • Overview of umbrella trials
  • What are the advantages of using this type trial design?
    • Reduction of cost, patient access, accelerated development
  • Efforts to create an immunotherapy clinical trial platform within the trial design to allow for running of multiple studies at the same time.
Nov 2812:20
Conference pass

Tools to identify, predict and prioritize vaccine candidates

Immuno-Oncology
  • Clinical challenges in cancer immunotherapy.
  • Personalized cancer vaccines have the potential to enhance the efficacy of checkpoint inhibitors but predicting them from somatic mutations is a formidable challenge
  • Overview of approach to build better vaccine cocktails.
  • Understand integrated genomics and cell-based solutions in the cancer immunotherapy space, including application of whole transcriptome analysis to characterize the tumor microenvironment and biomarker discovery approaches to predict patient response.
Nov 2812:35
Conference pass

Panel: How will we integrate knowledge gained from the UIVI and other research into the development of a Universal Influenza Vaccine?

Vaccine Development
Nov 2812:35
Conference pass

Use of peptide antigens in immune-oncology vaccines and T-cell therapeutics

Immuno-Oncology
Nov 2812:50
Conference pass

Immunomic is addressing the challenges of viral targets in cancer

Immuno-Oncology
  • Immunomic is addressing the challenges in I-O by applying our proven UNITE technology platform
  • LAMP-based nucleic acid immunotherapies have the potential to broaden the current use of cancer immunotherapy by complementing approved and investigational approaches.
  • LAMP-based nucleic acid immunotherapy has potential as cancer immunotherapy in two general ways:
    • Activation of the immune system against highly immunogenic tumor types, potentially amplifying the response seen with checkpoint inhibitors
    • Creation of a new, robust immune response to tumor types that don’t otherwise provoke an immune reaction, by reconfiguring a critical component of our immune system
  • Several discovery stage programs for virally driven cancers including MCC, NPC/Gastric and HCC. INDs to be filed for these programs in 2019.
Nov 2812:50
Conference pass

Understanding which patients are most likely to responds using precision medicine tools – using MSI as a biomarker

Clinical Trials
Nov 282:00
Conference pass

Lunchtime presentation & book signing: “Vaccines did not cause Rachel’s Autism”

Keynotes
Nov 282:50
Conference pass

A live attenuated pertussis vaccine to prevent disease, colonization and transmission

Vaccine Development
  • Why we need aB. pertussisvaccine that induces potentmucosal immunity
  • Relationship between colonizing nasopharyngeal infection and disease
  • Mechanism of action for a live attenuated intranasal vaccine
  • Non-human primate challenge model data
  • Clinical study results
Nov 282:50
Conference pass

Next generation platform for the development of personalized synthetic cancer vaccines

Immuno-Oncology
  • Development of vaccine platform from concept to delivery
    • Bioinformatic immunogen design, use of long peptides and heat shock proteins
  • Challenges of working with peptides
  • Selecting the correct mutations in each patient
  • Parallel approach to selecting neoantigens represented by abnormal post-translational modifications
  • Potential for combination therapy
Nov 282:50
Conference pass

Clinical trial analysis – What end-points should we be using now that PFS is not robust and OS may be contaminated by cross-over?

Clinical Trials
Nov 283:20
Conference pass

Pertussis and Pertussis vaccines; mistakes made during a 112 year odyssey and what some of those mistakes bode for the future

Vaccine Development
  • During the 20th century, B. pertussis was extensively studied in animal model systems and many “toxins” and protective antigens were described.
  • DTaP vaccines were developed and put into general use in the USA in 1997.
  • During the last 13 years, major pertussis epidemics have occurred in the USA due to deficiencies in DTaP vaccines.
  • Two of the deficiencies are the small number of antigens and the type of cellular immune response.
  • The small number of antigens leads to linked-epitope suppression.
  • Because of linked-epitope suppression, all children who were primed by DTaP vaccines will be more susceptible to pertussis throughout their lifetimes.
Nov 283:20
Conference pass

Overcoming tumor immune suppression using a novel retroviral replicating vector

Immuno-Oncology
  • Pre-clinical data: observations to support immune mediated mechanism of action
  • Phase 1 data in recurrent high-grade glioma: durable complete responses seen in dose escalation studies
  • Clinical Development: Food and Drug Administration Breakthrough Therapy Designation, European Medicines Agency’s PRIME designation and Phase 3 trial in recurrent glioblastoma and anaplastic astrocytoma
  • Updates in studies for solid tumors
Nov 283:20
Conference pass

Clinical development of infectious disease vaccines using measles-based vector platform and application to immuno-oncology

Clinical Trials
Nov 283:50
Conference pass

Updates in the clinical development of a chikungunya vaccine

Vaccine Development
  • Trends in chikungunya epidemiology
  • VLP vaccine technology
  • Updates in phase 2 clinical trials
Nov 283:50
Conference pass

The next wave: development of BCMA CAR-T therapies for multiple myeloma

Immuno-Oncology
Nov 283:50
Conference pass

Getting Closer to the Market: BiondVax's Universal Flu Vaccine Pivotal Phase 3 Trial

Clinical Trials
  • M-001 technology
  • Phase 3 trial protocol
  • Plans for getting to the market
Nov 284:50
Conference pass

Progress towards licensure and deployment of a malaria vaccine

Vaccine Development
Nov 284:50
Conference pass

Creation of off-the-shelf TCR-less CAR T cell therapies

Immuno-Oncology
Nov 285:20
Conference pass

Panel: Is there a future for arbovirus vaccines?

Vaccine Development
  • What is the current landscape for dengue, zika and other arbovirus vaccines?
  • Which other arboviruses should be prioritized for vaccine development or for improvements of the existing vaccine(s)?
  • What might emerging arboviruses look like and what improvements are needed in current vaccines?
  • Finding a better way to evaluate these vaccines before going into phase 3 trials.
  • Using human protection models to discover the keys to eliciting a protective immune response
  • How will the immune response to one virus affect that of another?
  • What are the challenges to funding and commercializing arbovirus vaccines?
Nov 285:20
Conference pass

Strategies for the development of safer and more effective CAR-T therapies

Immuno-Oncology
  • General strategies for CAR-T cell control
  • Defining small molecule vs antibody-based targeting – why we use Ab-based targeting.
  • Deep dive into the technicalities of designing these switches to control different targets
  • Universality of the platform and potential for use in solid tumors.
Nov 285:50
Conference pass

Allogenic vs autologous CAR-T therapies – pros and cons

Immuno-Oncology
Nov 285:50
Conference pass

Clinical development of a subunit based congenital CMV vaccine

Clinical Trials
  • Vaccine development for CMV: High unmet medical need
  • CMV vaccine development at GSK, past and present
  • Critical challenges facing CMV vaccine developers

Create your personal agenda –check the favourite icon

Nov 2908:30
Conference pass
Nov 2908:40
Conference pass

CEPI Vaccine Portfolio overview

Vaccine Development
Senior Representative, CEPI
Nov 2908:55
Conference pass

Advantages of the TriGrid delivery system for delivery of DNA vaccines

Delivery, Bioprocessing & Manufacturing
Nov 2909:10
Conference pass

A novel approach to developing single dose and safe vaccines for emerging infectious diseases

Vaccine Development
  • In vivo production of VLPs allows them to be more readily recognized by the immune system
  • Safety and durability of vaccines demonstrated in HIV clinical trials
  • Platform can be applied to multiple vaccine targets including; Ebola, Zika and Lassa
  • Differs from other platforms as there is no need for adjuvants and is thermally and genetically stable
Nov 2909:10
Conference pass

Expanding Vaccine Effectiveness with Needle-Free Delivery

Delivery, Bioprocessing & Manufacturing
  • Commercially available Needle-free delivery systems
  • Established clinical efficacy with commercial vaccines
  • Helping Nucleic Acid based vaccines toward licensure
Nov 2909:25
Conference pass

From neoantigen conjugates, to plasmid DNA vaccines, rapid response in small scale production towards personalized medicine

Delivery, Bioprocessing & Manufacturing
Nov 2909:40
Conference pass

Development of a replicating viral-vector based Lassa vaccine candidate

Vaccine Development
Nov 2909:40
Conference pass

A DNA vaccine platform to rapidly produce countermeasures against emerging viral threats

Delivery, Bioprocessing & Manufacturing
  • Describe a highly scalable manufacturing process for the rapid production of DNA-based vaccines for emerging infectious diseases
  • Discuss the stability profile of our DNA-based product
  • Offer a real-life example of a rapid response to an infectious disease – Zika
Nov 2911:30
Conference pass

Advances in adjuvant technology

Keynotes
Nov 2911:30
Conference pass

Clinical data integration – How do we deal with the volume of data generated by recent I-O trials?

Keynotes
Nov 2911:30
Conference pass

Considerations for successful cancer immunotherapy in aged hosts

Keynotes
Nov 2911:30
Conference pass

Development of predictive biomarkers to determine optimal combinations in precision immunotherapy

Keynotes
Nov 2911:30
Conference pass

Discovery of pre-clinical genomic biomarkers of safety and efficacy in vaccine research, design and development

Keynotes
Nov 2911:30
Conference pass

How can we improve speed, delivery and cost of next generation cancer vaccines?

Keynotes
Nov 2911:30
Conference pass

How can we streamline the vaccine manufacturing process to respond quickly to pandemics?

Keynotes
Nov 2911:30
Conference pass

Improving the accuracy of neoantigen identification

Keynotes
Nov 2911:30
Conference pass

Legal considerations for partnering with government bodies, pharma and biotechs

Keynotes
Nov 2911:30
Conference pass

New approaches for assessing T-Cell responses to vaccination

Keynotes
Nov 2911:30
Conference pass

Prospects and challenges for development of a Group A Streptococcal Vaccine

Keynotes
Nov 2911:30
Conference pass

Surveillance systems to comprehensively monitor the use and safety of vaccines during pregnancy

Keynotes
Nov 2911:30
Conference pass

What are investors looking for in emerging biotechs?

Keynotes
Nov 2911:30
Conference pass

What are the next steps when immunotherapy trials fail after receiving accelerated approval?

Keynotes
Nov 2911:30
Conference pass

What are we doing to target potential responders or enrich for potential responders in immuno-oncology?

Keynotes
Nov 292:10
Conference pass

Human challenge studies for universal influenza monoclonal antibodies

Vaccine Development
Dr Jerald Sadoff, Senior Advisor Vaccine Development, Janssen Infectious Diseases and Vaccines
Nov 292:10
Conference pass

Early clinical development of antibody drug conjugates: challenges and opportunities

Immuno-Oncology
Nov 292:10
Conference pass

Rapid cycle time, small-batch manufacturing technique for personalized cancer vaccines

Delivery, Bioprocessing & Manufacturing
Nov 292:40
Conference pass

Development of trispecific antibodies for the treatment of HIV and potential for application to other infectious diseases

Vaccine Development
  • Background on broadly neutralizing antibodies to HIV addressing potency and breadth of coverage
  • Potential for combinations of antibodies to provide optimum coverage for therapy or prevention of HIV infection
  • Pre-clinical development and testing of a trispecific anti-HIV antibody molecule
  • Update on clinical development and testing of a trispecific anti-HIV antibody molecule
Nov 292:40
Conference pass

Unique platforms for the development of ADCs and other antibody-based therapies using site-specific conjugation technology

Immuno-Oncology
Dr Arturo Molina, Chief Medical Officer, Sutro Biopharma
Nov 292:40
Conference pass

Pharmaceutical development and manufacturing strategies for delivering highly personalized cancer vaccines to patients

Delivery, Bioprocessing & Manufacturing
Nov 293:10
Conference pass

Development of monoclonal antibodies against Ebola and other filoviruses

Vaccine Development
Nov 293:10
Conference pass

Bispecific Technology for Multiple Avenues of T-cell Activation

Immuno-Oncology
  • Checkpoint bispecifics to improve therapeutic index: PD1 x CTLA4
  • Triple checkpoint blockade: LAG3 x CTLA4 bispecific plus anti-PD1
  • Checkpoint plus costim.: PD1 x ICOS
  • Potency-tuned IL15 for prolonged T cell stimulation
Nov 293:10
Conference pass

Vector-free vs Viral vector-based CAR-T manufacturing challenges and opportunities

Delivery, Bioprocessing & Manufacturing
Nov 294:10
Conference pass

Harnessing Natural Immunity to Create Breakthrough Therapies for Infectious Diseases

Vaccine Development
  • These antibodies are isolated from individuals with natural immunity against pathogens.
  • Antibody sequences are derived from unmodified heavy and light chain human B lymphocyte sequences that have undergone ontogeny and selection inside a human body.
  • Antibodies derived as a result of a human immune response are expected to exhibit high affinity, ideal safety and pharmacokinetics.
  • XBiotech’s discovery and production technologies help bring these novel therapeutics from bench to bedside in a relatively short timeframe
Nov 294:10
Conference pass

Bispecific therapies as monotherapies and in combination with checkpoint inhibitors

Immuno-Oncology
Dr Maria Karasarides, Executive Director, ImmunoOncology, Regeneron Pharmaceuticals
Nov 294:10
Conference pass

Advances in technology and ongoing challenges in the development of next generation antibody therapeutics

Delivery, Bioprocessing & Manufacturing
  • Overview of status of bispecific research – advantages of bispecific therapies vs two monotherapies
  • Alternative scaffolds for bispecific antibodies
  • Manufacturing strategies and challenges – production, engineering and stability
Nov 294:40
Conference pass

Development of a broadly neutralizing monoclonal antibody with extended half-life technology for the prevention of RSV in all infants

Vaccine Development
  • Overview of early discovery work
  • Updates from 2 completed clinical trials
  • New work on International Network for Optimal Resistance Monitoring (INFORM) RSV in collaboration with ReSViNET
Nov 294:40
Conference pass

Biologic and clinical activity of first in class ICOS agonist antibody in combination with checkpoint inhibitors

Immuno-Oncology
  • Preclinical rationale for development of JTX-2011, an ICOS agonist
  • Rationale for combinations with PD-1 inhibitors, CTLA-4 inhibitors, and vaccines
  • Clinical and biomarker data for JTX-2011 in patients with advanced solid tumors that supports further development
Nov 295:10
Conference pass

Immune Dampening and Refocusing for deriving novel biologics for difficult and unmet infectious disease and oncology applications

Vaccine Development
  • Addressing the problem of evolved immunodominance in antigenic structures
  • What is deceptive Imprinting and how does it work?
    • e.g. what is its evolutionary benefit?
  • What are the immuno-chemical-physical characteristics that drive it?
    • e.g. how can these be identified today and tomorrow?
  • What processes and technologies are available to overcome this evolved pathogen survival strategy?
    • Review Immune refocusing technology
Nov 295:10
Conference pass

Novel radioimmunotherapy product combining the targeting specificity of a monoclonal therapeutic antibody with the potency of radiation therapy

Immuno-Oncology
Dr Paul Maffuid, EVP Research and Development, MabVax Therapeutics Inc

Create your personal agenda –check the favourite icon

Nov 3009:00
Conference pass
Nov 3009:10
Conference pass

Single cell functionality serves as a predictive biomarker for overall survival of pancreatic cancer patients treated with GVAX vaccine

Immuno-Oncology
  • Polyfunctional Strength – the secretion of two more cytokines per cell, where the cytokine secretion intensity is tied to the cell which produced it, is a more accurate predictor of clinical outcome than flow cytometry, bulk protein analysis or gene array.
  • Single Cell Functionality has correlated with Objective Response across IO: CAR-T, Checkpoint Inhibitors and Cancer Vaccines
  • Polyfunctionality of CD4+ T-cells is a predictor of Overall Survival of patients treated with the GVAX Vaccine where post- versus pre-vaccination fold-change of the polyfunctional strength index was associated with patient overall survival (P = 0.001).
Nov 3009:10
Conference pass

Panel: How federal labs bring value to your company’s pipeline and bottom Line

Funding & Partnerships
  • What are federal labs looking for when partnering with biotech and pharma companies?
  • What are the current areas of interest?
  • What do you need to know about IP and future partnerships?
Nov 3009:40
Conference pass

FluoroSpot analysis of immune memory against malaria vaccine candidate antigens

Vaccine Development
  • Benefits and possibilities of the FluoroSpot assay in vaccine research
  • Studying the kinetics of malaria-specific B-cells after infection
  • Analysis of B cell cross-reactivity against polymorphic malaria antigen MSP-2
  • What the future might hold for the FluoroSpot assay
Nov 3009:40
Conference pass

An integrated machine-learning approach for improved prediction of clinically relevant neoantigens

Immuno-Oncology
  • Current neoantigen discovery algorithms are not optimal to predict presentation to the cell surface.
  • Here, we outline a high-performing machine learning approach, trained on mass-spectrometry data, that predicts naturally processed and presented antigens.
  • The predictor is integrated with several immune parameters, such as HLA binding, in a deep learning layer to predict bone fide neoantigens.
  • We illustrate its application to significantly improve the identification of neoantigen targets for personalized cancer immunotherapy
Nov 3009:55
Conference pass

Identification of novel mycobacterial factors involved in virulence and evasion of host immune responses in tuberculosis

Vaccine Development
Nov 3010:10
Conference pass

Investigating the effects of age and immunosenescence on influenza and vaccine-induced immunity

Vaccine Development
Nov 3010:10
Conference pass

A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States

Immuno-Oncology
  • Defining oncogenic states
  • Selecting 5-10 oncogenic states and identifying state-specific immunological targets, including immune checkpoints, neoantigens/anti-tumor epitopes, antibodies, and chimeric antigen receptors
  • Developing a multifactorial predictive model for eachoncogenic state to identify the most effective combinations
  • Validation of these perturbagens in isogenic cell systems, cancer cell lines, genetically engineered mouse models, and patient-derived xenografts
  • Insight into the development of novel treatment strategies
Nov 3010:10
Conference pass

Opportunities to drive innovation in life sciences – new areas of interest for big pharma on the west coast

Funding & Partnerships
  • What’s the current status of the industry?
  • Examples of the impact of disruptive technologies – what will the next ones be?
  • Examples of successful partnerships in recent years
  • Drive towards diagnostic tools to help achieve better outcomes sooner for patients in need.
  • Will the disproportionate investment in immuno-oncology have an impact in other therapeutic areas?
Nov 3011:40
Conference pass

A mechanistic understanding of the generation and regulation of T cell responses can inform superior vaccine development

Vaccine Development
Nov 3011:40
Conference pass

Technology Showcase 1: Supercharging immunotherapy targeting infectious disease & cancer

Funding & Partnerships
Nov 3012:10
Conference pass

Using predictive models to interrogate human immunity

Vaccine Development
Nov 3012:10
Conference pass

Panel: Integrating our understanding of the tumor microenvironment and the microbiome to inform the development of I-O treatment

Immuno-Oncology
  • Our current understanding the biology of the tumor microenvironment and microbiome in cancer.
  • How can we apply this to the development of novel immunotherapies?
  • Examples of data sharing efforts and industry/ academic collaborations
Nov 3012:40
Conference pass

Viral changes and antibody features that could provide a possible template for vaccine design

Vaccine Development
Nov 302:20
Conference pass

Accelerating progress of precision immunotherapy from laboratory to clinic through strategic collaborations

Keynotes
  • Progress through research, clinical trials and genomic analysis
  • Will these projects lead to us grouping cancers differently, e.g. according to genetic faults?
  • How are we working together to integrate this work and ensure we make therapies available to patients rapidly?
Nov 303:20
Conference pass

Leveraging the power of AI & machine learning for accelerated vaccine & immunotherapy development

Keynotes
  • Applications of machine learning and predictive modeling
  • Using machine learning techniques to decipher the human microbiome
  • The increasing complexity of genomic data
  • How can we translate the success seen in precision medicine to chronic diseases?
  • Connecting deep phenotyping to genetics
  • Examples of collaborations and exciting new technologies.
last published: 14/Sep/18 10:45 GMT

Sign Up for Event Updates

Contact us

To sponsor or exhibit contact:
Oliver Breed
+44 (0)207 092 1156

oliver.breed@terrapinn.com


To speak:
Lauren Sheppard
+44 (0)207 092 1211

lauren.sheppard@terrapinn.com